Published in Medical Device Business Week, May 10th, 2006
Under the agreement, Alnylam will collaborate with USAMRIID to discover RNAi therapeutics targeting viral organisms, including hemorrhagic fever viruses, which pose a serious biological threat to the military and public health of the United States.
"USAMRIID is actively seeking promising technologies to protect our armed forces, and we believe Alnylam's RNAi therapeutic platform enables the rapid discovery and development of anti-virals designed to be broad in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.